Filing Flows › Zenas BioPharma (ZBIO) › Q2 2026
Zenas BioPharma (ZBIO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 13, 2026
Zenas BioPharma (ZBIO) reported revenue of $1.0M for the second quarter 2026 (Q2 2026).
Revenue$1.0M
Year over year—
Quarter over quarter—
Operating margin—
Net earnings−$111M
Zenas BioPharma, Q2 2026: revenue $1.0M, net loss $111M, operating cash flow −$57.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.0M | — | — |
| Operating profit | −$108M | — | — |
| Net earnings | −$111M | — | — |
| Operating cash flow | −$57.2M | — | — |
What changed
Revenue was $1.0M in Q2 2026.
Operating costs exceeded revenue by $107.7M, an operating margin of -10765.9%. The quarter ended with a net loss of $111.5M.
Operating cash flow was −$57.2M. Non-cash charges added back $4K of depreciation and $8.6M of share-based compensation. Working capital and other items added $45.6M.
Questions
What was Zenas BioPharma's revenue in the second quarter 2026?
Zenas BioPharma (ZBIO) reported revenue of $1.0M for the second quarter 2026 (Q2 2026).
Source: Zenas BioPharma 10-Q on SEC EDGAR.